References
- Siegel, R., Ma, J., Zou, Z. and Jemal, A. (2014) Cancer statistics, 2014. Ca Cancer J. Clin., 64, 9-29. https://doi.org/10.3322/caac.21208
- Hanahan, D. and Weinberg, R.A. (2011) Hallmarks of cancer: the next generation. Cell, 144, 646-674. https://doi.org/10.1016/j.cell.2011.02.013
- Cantor, J.R. and Sabatini, D.M. (2012) Cancer cell metabolism: one hallmark, many faces. Cancer Discovery, 2, 881-898. https://doi.org/10.1158/2159-8290.CD-12-0345
- Chen, X., Qian, Y. and Wu, S. (2014) The warburg effect: Evolving interpretations of an established concept. Free Radical Biol. Med., Epub ahead of print.
- Phan, L.M., Yeung, S.C. and Lee, M.H. (2014) Cancer metabolic reprogramming: importance, main features, and potentials for precise targeted anti-cancer therapies. Cancer Biol. Med., 11, 1-19.
- Hanahan, D. and Weinberg, R.A. (2000) The hallmarks of cancer. Cell, 100, 57-70. https://doi.org/10.1016/S0092-8674(00)81683-9
- Warburg, O.H. (1930) The Metabolism of Tumours: Investigations from the Kaiser Wilhelm Institute for Biology, Berlin-Dahlem. Arnold Constable, London, pp. 1-327.
- Koppenol, W.H., Bounds, P.L. and Dang, C.V. (2011) Otto Warburg's contributions to current concepts of cancer metabolism. Nat. Rev. Cancer, 11, 325-337. https://doi.org/10.1038/nrc3038
- Rask-Andersen, M., Zhang, J., Fabbro, D. and Schioth, H.B. (2014) Advances in kinase targeting: current clinical use and clinical trials. Trends Pharmacol. Sci., 35, 604-620. https://doi.org/10.1016/j.tips.2014.09.007
- Nahta, R. and Esteva, F.J. (2007) Trastuzumab: triumphs and tribulations. Oncogene, 26, 3637-3643. https://doi.org/10.1038/sj.onc.1210379
- Ramos, P. and Bentires-Alj, M. (2014) Mechanism-based cancer therapy: resistance to therapy, therapy for resistance. Oncogene, Epub ahead of print.
- Garber, K. (2006) Energy deregulation: licensing tumors to grow. Science, 312, 1158-1159. https://doi.org/10.1126/science.312.5777.1158
- Vander Heiden, M.G., Cantley, L.C. and Thompson, C.B. (2009) Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science, 324, 1029-1033. https://doi.org/10.1126/science.1160809
- Granchi, C., Fancelli, D. and Minutolo, F. (2014) An update on therapeutic opportunities offered by cancer glycolytic metabolism. Bioorg. Med. Chem. Lett., 24, 4915-4925. https://doi.org/10.1016/j.bmcl.2014.09.041
- Pathania, D., Millard, M. and Neamati, N. (2009) Opportunities in discovery and delivery of anticancer drugs targeting mitochondria and cancer cell metabolism. Adv. Drug Delivery Rev., 61, 1250-1275. https://doi.org/10.1016/j.addr.2009.05.010
- Bellance, N., Lestienne, P. and Rossignol, R. (2009) Mitochondria: from bioenergetics to the metabolic regulation of carcinogenesis. Front. Biosci. (Landmark Ed.), 14, 4015-4034.
- Seyfried, T.N., Flores, R.E., Poff, A.M. and D'Agostino, D.P. (2014) Cancer as a metabolic disease: implications for novel therapeutics. Carcinogenesis, 35, 515-527. https://doi.org/10.1093/carcin/bgt480
- Coller, H.A. (2014) Is cancer a metabolic disease? Am. J. Pathol., 184, 4-17. https://doi.org/10.1016/j.ajpath.2013.07.035
- Evans, J.M., Donnelly, L.A., Emslie-Smith, A.M., Alessi, D.R. and Morris, A.D. (2005) Metformin and reduced risk of cancer in diabetic patients. BMJ, 330, 1304-1305. https://doi.org/10.1136/bmj.38415.708634.F7
- Pernicova, I. and Korbonits, M. (2014) Metformin--mode of action and clinical implications for diabetes and cancer. Nat. Rev. Endocrinol., 10, 143-156. https://doi.org/10.1038/nrendo.2013.256
- Menendez, J.A., Quirantes-Pine, R., Rodriguez-Gallego, E., Cufi, S., Corominas-Faja, B., Cuyas, E., Bosch-Barrera, J., Martin-Castillo, B., Segura-Carretero, A. and Joven, J. (2014) Oncobiguanides: Paracelsus' law and nonconventional routes for administering diabetobiguanides for cancer treatment. Oncotarget, 5, 2344-2348.
- Bridges, H.R., Jones, A.J., Pollak, M.N. and Hirst, J. (2014) Effects of metformin and other biguanides on oxidative phosphorylation in mitochondria. Biochem. J., 462, 475-487. https://doi.org/10.1042/BJ20140620
- Pessayre, D., Fromenty, B., Berson, A., Robin, M.A., Letteron, P., Moreau, R. and Mansouri, A. (2012) Central role of mitochondria in drug-induced liver injury. Drug Metab. Rev., 44, 34-87. https://doi.org/10.3109/03602532.2011.604086
- Szczepanek, K., Chen, Q., Larner, A.C. and Lesnefsky, E.J. (2012) Cytoprotection by the modulation of mitochondrial electron transport chain: the emerging role of mitochondrial STAT3. Mitochondrion, 12, 180-189. https://doi.org/10.1016/j.mito.2011.08.011
- Vaupel, P., Hockel, M. and Mayer, A. (2007) Detection and characterization of tumor hypoxia using pO2 histography. Antioxid. Redox Signaling, 9, 1221-1235. https://doi.org/10.1089/ars.2007.1628
- Hirayama, A., Kami, K., Sugimoto, M., Sugawara, M., Toki, N., Onozuka, H., Kinoshita, T., Saito, N., Ochiai, A., Tomita, M., Esumi, H. and Soga, T. (2009) Quantitative metabolome profiling of colon and stomach cancer microenvironment by capillary electrophoresis time-of-flight mass spectrometry. Cancer Res., 69, 4918-4925. https://doi.org/10.1158/0008-5472.CAN-08-4806
- Birsoy, K., Possemato, R., Lorbeer, F.K., Bayraktar, E.C., Thiru, P., Yucel, B., Wang, T., Chen, W.W., Clish, C.B. and Sabatini, D.M. (2014) Metabolic determinants of cancer cell sensitivity to glucose limitation and biguanides. Nature, 508, 108-112. https://doi.org/10.1038/nature13110
- McKenzie, M., Liolitsa, D. and Hanna, M.G. (2004) Mitochondrial disease: mutations and mechanisms. Neurochem. Res., 29, 589-600. https://doi.org/10.1023/B:NERE.0000014829.42364.dd
- Salminen, A., Ojala, J., Kaarniranta, K. and Kauppinen, A. (2012) Mitochondrial dysfunction and oxidative stress activate inflammasomes: impact on the aging process and agerelated diseases. Cell. Mol. Life Sci., 69, 2999-3013. https://doi.org/10.1007/s00018-012-0962-0
- Bonora, E., Porcelli, A.M., Gasparre, G., Biondi, A., Ghelli, A., Carelli, V., Baracca, A., Tallini, G., Martinuzzi, A., Lenaz, G., Rugolo, M. and Romeo, G. (2006) Defective oxidative phosphorylation in thyroid oncocytic carcinoma is associated with pathogenic mitochondrial DNA mutations affecting complexes I and III. Cancer Res., 66, 6087-6096. https://doi.org/10.1158/0008-5472.CAN-06-0171
- Szablewski, L. (2013) Expression of glucose transporters in cancers. Biochim. Biophys. Acta, 1835, 164-169.
- Zhang, X., Fryknas, M., Hernlund, E., Fayad, W., De Milito, A., Olofsson, M.H., Gogvadze, V., Dang, L., Pahlman, S., Schughart, L.A., Rickardson, L., D'Arcy, P., Gullbo, J., Nygren, P., Larsson, R. and Linder, S. (2014) Induction of mitochondrial dysfunction as a strategy for targeting tumour cells in metabolically compromised microenvironments. Nat. Commun., 5, 3295.
- Viale, A., Pettazzoni, P., Lyssiotis, C.A., Ying, H., Sanchez, N., Marchesini, M., Carugo, A., Green, T., Seth, S., Giuliani, V., Kost-Alimova, M., Muller, F., Colla, S., Nezi, L., Genovese, G., Deem, A.K., Kapoor, A., Yao, W., Brunetto, E., Kang, Y., Yuan, M., Asara, J.M., Wang, Y.A., Heffernan, T.P., Kimmelman, A.C., Wang, H., Fleming, J.B., Cantley, L.C., DePinho, R.A. and Draetta, G.F. (2014) Oncogene ablationresistant pancreatic cancer cells depend on mitochondrial function. Nature, 514, 628-632. https://doi.org/10.1038/nature13611
- Le, A., Stine, Z.E., Nguyen, C., Afzal, J., Sun, P., Hamaker, M., Siegel, N.M., Gouw, A.M., Kang, B.H., Yu, S.H., Cochran, R.L., Sailor, K.A., Song, H. and Dang, C.V. (2014) Tumorigenicity of hypoxic respiring cancer cells revealed by a hypoxiacell cycle dual reporter. Proc. Natl. Acad. Sci. U.S.A., 111, 12486-12491. https://doi.org/10.1073/pnas.1402012111
- Osada-Oka, M., Hashiba, Y., Akiba, S., Imaoka, S. and Sato, T. (2010) Glucose is necessary for stabilization of hypoxiainducible factor-1alpha under hypoxia: contribution of the pentose phosphate pathway to this stabilization. FEBS Lett., 584, 3073-3079. https://doi.org/10.1016/j.febslet.2010.05.046
- Semenza, G.L. (2003) Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer, 3, 721-732. https://doi.org/10.1038/nrc1187
- Gasparre, G., Porcelli, A.M., Lenaz, G. and Romeo, G. (2013) Relevance of mitochondrial genetics and metabolism in cancer development. Cold Spring Harbor Perspect. Biol., 5, a011411.
- Pike Winer, L.S. and Wu, M. (2014) Rapid analysis of glycolytic and oxidative substrate flux of cancer cells in a microplate. PLoS One, 9, e109916. https://doi.org/10.1371/journal.pone.0109916
- Habano, W., Sugai, T., Yoshida, T. and Nakamura, S. (1999) Mitochondrial gene mutation, but not large-scale deletion, is a feature of colorectal carcinomas with mitochondrial microsatellite instability. Int. J. Cancer, 83, 625-629. https://doi.org/10.1002/(SICI)1097-0215(19991126)83:5<625::AID-IJC10>3.0.CO;2-N
- Jeronimo, C., Nomoto, S., Caballero, O.L., Usadel, H., Henrique, R., Varzim, G., Oliveira, J., Lopes, C., Fliss, M.S. and Sidransky, D. (2001) Mitochondrial mutations in early stage prostate cancer and bodily fluids. Oncogene, 20, 5195-5198. https://doi.org/10.1038/sj.onc.1204646
- Maximo, V., Soares, P., Lima, J., Cameselle-Teijeiro, J. and Sobrinho-Simoes, M. (2002) Mitochondrial DNA somatic mutations (point mutations and large deletions) and mitochondrial DNA variants in human thyroid pathology: a study with emphasis on Hurthle cell tumors. Am. J. Pathol., 160, 1857-1865. https://doi.org/10.1016/S0002-9440(10)61132-7
- Costa-Guda, J., Tokura, T., Roth, S.I. and Arnold, A. (2007) Mitochondrial DNA mutations in oxyphilic and chief cell parathyroid adenomas. BMC Endocr. Disord., 7, 8. https://doi.org/10.1186/1472-6823-7-8
- Gasparre, G., Porcelli, A.M., Bonora, E., Pennisi, L.F., Toller, M., Iommarini, L., Ghelli, A., Moretti, M., Betts, C.M., Martinelli, G.N., Ceroni, A.R., Curcio, F., Carelli, V., Rugolo, M., Tallini, G. and Romeo, G. (2007) Disruptive mitochondrial DNA mutations in complex I subunits are markers of oncocytic phenotype in thyroid tumors. Proc. Natl. Acad. Sci. U.S.A., 104, 9001-9006. https://doi.org/10.1073/pnas.0703056104
- Gasparre, G., Hervouet, E., de Laplanche, E., Demont, J., Pennisi, L.F., Colombel, M., Mege-Lechevallier, F., Scoazec, J.Y., Bonora, E., Smeets, R., Smeitink, J., Lazar, V., Lespinasse, J., Giraud, S., Godinot, C., Romeo, G. and Simonnet, H. (2008) Clonal expansion of mutated mitochondrial DNA is associated with tumor formation and complex I deficiency in the benign renal oncocytoma. Hum. Mol. Genet., 17, 986-995. https://doi.org/10.1093/hmg/ddm371
- Dasgupta, S., Koch, R., Westra, W.H., Califano, J.A., Ha, P.K., Sidransky, D. and Koch, W.M. (2010) Mitochondrial DNA mutation in normal margins and tumors of recurrent head and neck squamous cell carcinoma patients. Cancer Prev. Res. (Philadelphia), 3, 1205-1211. https://doi.org/10.1158/1940-6207.CAPR-10-0018
- Porcelli, A.M., Ghelli, A., Ceccarelli, C., Lang, M., Cenacchi, G., Capristo, M., Pennisi, L.F., Morra, I., Ciccarelli, E., Melcarne, A., Bartoletti-Stella, A., Salfi, N., Tallini, G., Martinuzzi, A., Carelli, V., Attimonelli, M., Rugolo, M., Romeo, G. and Gasparre, G. (2010) The genetic and metabolic signature of oncocytic transformation implicates HIF1alpha destabilization. Hum. Mol. Genet., 19, 1019-1032. https://doi.org/10.1093/hmg/ddp566
- Ye, F., Samuels, D.C., Clark, T. and Guo, Y. (2014) Highthroughput sequencing in mitochondrial DNA research. Mitochondrion, 17, 157-163. https://doi.org/10.1016/j.mito.2014.05.004
- Singh, A.K., Pandey, P., Tewari, M., Pandey, H.P. and Shukla, H.S. (2014) Human mitochondrial genome flaws and risk of cancer. Mitochondrial DNA, 25, 329-334. https://doi.org/10.3109/19401736.2013.796520
- Damas, J., Samuels, D.C., Carneiro, J., Amorim, A. and Pereira, F. (2014) Mitochondrial DNA rearrangements in health and disease--a comprehensive study. Hum. Mutat., 35, 1-14. https://doi.org/10.1002/humu.22452
- Ju, Y.S., Alexandrov, L.B., Gerstung, M., Martincorena, I., Nik-Zainal, S., Ramakrishna, M., Davies, H.R., Papaemmanuil, E., Gundem, G., Shlien, A., Bolli, N., Behjati, S., Tarpey, P.S., Nangalia, J., Massie, C.E., Butler, A.P., Teague, J.W., Vassiliou, G.S., Green, A.R., Du, M.Q., Unnikrishnan, A., Pimanda, J.E., Teh, B.T., Munshi, N., Greaves, M., Vyas, P., El-Naggar, A.K., Santarius, T., Collins, V.P., Grundy, R., Taylor, J.A., Hayes, D.N., Malkin, D., Foster, C.S., Warren, A.Y., Whitaker, H.C., Brewer, D., Eeles, R., Cooper, C., Neal, D., Visakorpi, T., Isaacs, W.B., Bova, G.S., Flanagan, A.M., Futreal, P.A., Lynch, A.G., Chinnery, P.F., McDermott, U., Stratton, M.R. and Campbell, P.J. (2014) Origins and functional consequences of somatic mitochondrial DNA mutations in human cancer. eLife, 3, e02935.
- Jones, J.B., Song, J.J., Hempen, P.M., Parmigiani, G., Hruban, R.H. and Kern, S.E. (2001) Detection of mitochondrial DNA mutations in pancreatic cancer offers a "mass"-ive advantage over detection of nuclear DNA mutations. Cancer Res., 61, 1299-1304.
- Lai, C.H., Huang, S.F., Liao, C.T., Chen, I.H., Wang, H.M. and Hsieh, L.L. (2013) Clinical significance in oral cavity squamous cell carcinoma of pathogenic somatic mitochondrial mutations. PLoS One, 8, e65578. https://doi.org/10.1371/journal.pone.0065578
Cited by
- The Landscape of mtDNA Modifications in Cancer: A Tale of Two Cities vol.7, pp.2234-943X, 2017, https://doi.org/10.3389/fonc.2017.00262